Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

Menu

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
Menu
My View
  • Edit
  • Add your favourite topics for quick access
Meet the Team
Ask the Analyst
Partnered Content
PDF Library
RSS Feeds
Subscribe
Advertising
Report Store
UsernamePublicRestriction
Tags:
Consumer OTC Drugs

House Commerce/Health Subcommittee ranking Democrat is Ohio's Sherrod Brown.

This article was originally published in The Tan Sheet

  • News
  • The Tan Sheet

Executive Summary

HOUSE COMMERCE/HEALTH SUBCMTE. RANKING DEMOCRAT REP. BROWN is a two-term congressman from Ohio who has taken positions on price and quality controls in the home infusion market and supported an extension of the federal market for a segment of the health care industry in his home district. During his initial run for the House in 1992, Sherrod Brown pledged to make health care reform a priority, stressing his support for universal access to health care and cost-containment measures. His official biography asserts that Brown "fought against price gouging by certain segments of the medical industry."

You may also be interested in...



People In Brief

Perrigo promotes in pricing, planning

In Brief

Combe sells most of its OTC brands

Supplement GMP Warning Letters Make Modest Debut In 2010

Finalization of a settlement between the Federal Trade Commission and Rexall Sundown regarding unsupported cellulite treatment claims for the firm's Cellasene dietary supplement hinges upon approval of two related class action settlements pending in California and Florida, according to FTC

Table

View full table

Topics

Tags:
Consumer OTC Drugs
UsernamePublicRestriction

Register

PS086598

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By